Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors

This article was originally published here

This medicine is currently in Phase III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+) breast and specific gastric cancer tumors. The agreement

The post Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply